Mirnext is a newly established biomedical company focusing on the discovery, validation and commercialization of miRNAs as novel biomarkers for cardiovascular disease. The company develops actionable and cost-effective multimarker tests to improve diagnostic routine and clinical management of patients entering the clinic with symptoms of heart failure or coronary artery disease.
Mirnext concentrates on developing novel microRNA (miRNA) biomarkers for the diagnosis and prognosis of patients with heart failure. miRNAs represent a new class of circulating biomarkers that are remarkably stable and can be easily detected in blood samples. Mirnext identified a series of microRNAs that can be used for the diagnosis and prognosis of heart failure.
In current practice clinical symptoms and multiple measurements of diagnostic biomarkers (BNP, NTproBNP) and of prognostic markers such as Galectin-3 are required to optimally assess the clinical condition of a heart failure patient.
The key objective of Mirnext is to develop one multi-marker test that simultaneously provides diagnostic and prognostic information and can distinguish between the different heart failure subtypes. A quick and simplified diagnostic procedure that leads to a better understanding of the cardiovascular status will result in better treatment decisions and improved patient outcomes.